Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Annual report

Annual Report 2022 Sequana Medical

Annual report 2022
Download

Annual report 2021
Download

Annual report 2020
Download

Annual report 2019
Download

Annual report 2018
Download

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES